STRUCTURED ABSTRACT Background Cancer treatment has undergone a revolution in efficacy over the past three decades. Survival rates have improved dramatically across virtually every major cancer type, and the population of cancer survivors in the United States alone is projected to exceed 22 million by 2030. Yet as survival has improved, a critical and largely unaddressed consequence has emerged: a significant proportion of survivors completing treatment experience persistent motivational flatness, cognitive slowing, anhedonia, and executive dysfunction that extends well beyond the acute treatment period, resists resolution through rest or standard antidepressant therapy, and profoundly diminishes quality of life. This syndrome has been variably described as chemobrain, cancer-related cognitive impairment, and post-cancer malaise. However, these labels share a common limitation: they frame the syndrome primarily through a cognitive and chemotherapy-specific lens, failing to capture the motivational and reward-processing deficits that render it neurobiologically distinct, and failing to account for the full spectrum of cancer treatments now known to produce equivalent or overlapping neurobiological disruption. Purpose This paper proposes Treatment-Induced Dopaminergic Dysfunction (TIDD) as an expanded and unified neurobiological framework that extends beyond the chemotherapy-specific model introduced in the author's prior published work on Chemotherapy-Induced Dopaminergic Dysfunction (CIDD) (Kiesewetter, 2026). TIDD synthesizes peer-reviewed literature across four confirmed treatment modalities — cytotoxic chemotherapy, cranial and head/neck radiation, hormone suppression therapy, and chronic tyrosine kinase inhibitor therapy — to demonstrate that mesolimbic dopamine pathway disruption, HPA axis dysregulation, neuroinflammation, and autonomic dysregulation are not chemotherapy-specific phenomena but rather a common neurobiological consequence of the physiological burden imposed by cancer treatment more broadly. The framework is intended to facilitate more targeted clinical evaluation and treatment discussions across oncology subspecialties, and to address a critical and growing gap in survivorship care for the expanding population of long-term cancer survivors. Methods This paper presents a synthesized clinical framework based on a narrative review of peer-reviewed literature spanning oncology, neurology, endocrinology, neuro-oncology, palliative medicine, and survivorship medicine. Literature was identified through PubMed, PMC, and related databases using terms including treatment-induced cognitive impairment, dopaminergic dysfunction, mesolimbic pathway disruption, HPA axis dysregulation, neuroinflammation, cancer survivorship, androgen deprivation therapy cognitive effects, cranial radiation dopamine, tyrosine kinase inhibitor fatigue, and related terms. Priority was given to peer-reviewed primary literature, systematic reviews, and meta-analyses. Results The TIDD framework identifies a convergent neurobiological mechanism across four confirmed treatment modalities. Cytotoxic chemotherapy, particularly platinum-based agents, disrupts the mesolimbic dopamine pathway, NMDA receptor function, and triggers neuroinflammatory cytokine cascades. Cranial and head/neck radiation produces direct and prolonged suppression of ventral tegmental area dopamine neuronal function with documented reductions in VTA-prefrontal connectivity. Hormone suppression therapy — including androgen deprivation therapy in prostate cancer, aromatase inhibitors in breast cancer, and TSH suppression in thyroid cancer — disrupts hypothalamic dopaminergic tone through HPG axis modulation. Chronic tyrosine kinase inhibitor therapy used in blood cancers produces treatment-related fatigue consistent with the TIDD phenotype, with second-generation TKIs demonstrating direct blood-brain barrier penetration and documented dopaminergic effects. A fifth modality — radioactive iodine therapy — is identified as an area of emerging mechanistic evidence warranting further primary research. Across all confirmed modalities, the clinical phenotype converges on the same presentation: motivational flatness, cognitive inertia, anhedonia, executive dysfunction, and a subjective sense of reward circuitry disruption that survivors consistently describe as qualitatively distinct from depression, fatigue, or post-treatment adjustment. Conclusions TIDD represents a clinically significant, neurobiologically coherent, and deeply underserved dimension of the cancer survivorship experience that extends far beyond the chemotherapy-treated population previously addressed by the CIDD framework. The convergence of dopaminergic pathway disruption, HPA axis dysregulation, and neuroinflammation across multiple treatment modalities suggests a unified survivorship syndrome affecting potentially millions of survivors across cancer types and treatment histories. Clinical recognition, targeted pharmacological intervention, and HSP-informed psychotherapeutic support offer meaningful pathways toward improved survivorship outcomes. This framework is offered as a foundation for prospective clinical investigation and as an actionable resource for the multidisciplinary survivorship care community.
James M. Kiesewetter (Fri,) studied this question.